Jiushi Shenkang closes Series A financing round, raises nearly RMB100m

Jiushi Shenkang has raised nearly 100 million yuan in a Series A financing round. This round of financing was led by Apricot Capital. The proceeds will be used to promote the clinical research of new products of its neural intervention product pipeline, and the marketing and industrialization of the subsequent product launching.

Jiushi Shenkang has raised nearly 100 million yuan in a Series A financing round. This round of financing was led by Apricot Capital. The proceeds will be used to promote the clinical research of new products of its neural intervention product pipeline, and the marketing and industrialization of the subsequent product launching.

Established in 2016, Jiushi Shenkang is a R&D-driven enterprise mainly engaged in the research and development and commercialization of Class III neurological interventional medical devices. It is oriented to meet clinical needs and deploys a variety of therapeutic neuro-interventional products, covering the two major sectors of ischemic and hemorrhagic stroke.

At present, the company has four major product lines for the treatment of intracranial aneurysms, acute ischemic stroke thrombectomy, stroke pathway products and stroke stenosis treatment respectively.

Lv Weiyan, the founder of Jiushi Shenkang, has worked in Microport and Lepu Medical before starting his own business. He has been responsible for and participated in the research and development and industrialization of more than 20 cardiovascular and cerebrovascular interventional medical devices to the market.

The company’s core team members are from various leading medical device companies in China, and each person has more than 10 years of experience in medical device development and industrialization on average.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/06/04/jiushi-shenkang-closes-series-a-financing-round-raises-nearly-rmb100m/.

Leave a Reply

Please Login to Comment